Zdrowie i gospodarka · 03/04/2019
FDA to Hold Public Hearing on Biosimilar Insulin Products
The FDA is hosting a public hearing to address access to affordable insulin and the development of biosimilar and interchangeable insulin products, following a request for comments on the topic.
Source: Federal Register — Food and Drug AdministrationOpen original release →